Recently, a research team led by Professor Jian-Xun Wang and Professor Tao Yu from Qingdao University made a significant ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.